Vaxart Inc (VXRT NASDAQ) stock market data APIs
$0.3646
0.03(8.2%)
as of September 15, 2025
Try our APIs with
free plan!
Vaxart Inc Financial Data Overview
Price chart is built with
Anychart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Prev. Close
0.3646
Open
0.3901
High
0.3901
Low
0.3645
52 wk Range
0.2606-0.98
Market Cap
83 120 K
Shares Outstanding
229 M
Revenue
80 724 K
EPS
-0.07
Beta
1.332
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Vaxart Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vaxart Inc data using free add-ons & libraries
Get Vaxart Inc Fundamental Data
Vaxart Inc Fundamental data includes:
- Net Revenue: 80 724 K
- EBITDA: -46 601 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vaxart Inc News
New
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SA...
Concerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special Meeting
Question Board’s Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes ATLANTA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Danie...
Vaxart Announces Adjournment of Special Meeting of Stockholders
Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations a...
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral reco...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
